Macrolide-resistant Mycoplasma pneumoniae infection prevalence increases again in Osaka

IF 2 Q2 RESPIRATORY SYSTEM Respiratory investigation Pub Date : 2025-07-01 Epub Date: 2025-04-22 DOI:10.1016/j.resinv.2025.04.009

Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito

{"title":"Macrolide-resistant Mycoplasma pneumoniae infection prevalence increases again in Osaka","authors":"Naoyuki Miyashita, Makoto Ogata, Naoki Fukuda, Akihisa Yamura, Tomoki Ito","doi":"10.1016/j.resinv.2025.04.009","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>We investigated the prevalence rate and resistance mechanism of macrolide-resistant <em>Mycoplasma pneumoniae</em> strains between 2018 and 2024.</div></div><div><h3>Methods</h3><div>We analyzed 367 patients with <em>M. pneumoniae</em> infection by the polymerase chain reaction method.</div></div><div><h3>Results</h3><div>Macrolide-resistant <em>M. pneumoniae</em> was identified in nine of 51 patients (17.6 %) in 2018, 13 of 63 patients (20.6 %) in 2019, eight of 30 patients (26.7 %) in 2020, one of three patients in 2021, one of three patients in 2022, three of six patients in 2023, and 127 of 211 patients (60.2 %) in 2024. Prevalence of macrolide-resistant <em>M. pneumoniae</em> was significantly increased in 2024 compared to the years 2018–2020 (<em>p</em> < 0.0001). The majority of resistant strains had an A-to-G transition at position 2063 in the <em>M. pneumoniae</em> 23S rRNA domain V gene region, which is associated with high-level resistance to macrolides.</div></div><div><h3>Conclusions</h3><div>Our study demonstrated that the prevalence of macrolide-resistant <em>M. pneumoniae</em> is once again increasing in Osaka Prefecture.</div></div>","PeriodicalId":20934,"journal":{"name":"Respiratory investigation","volume":"63 4","pages":"Pages 517-520"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory investigation","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2212534525000516","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/22 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

We investigated the prevalence rate and resistance mechanism of macrolide-resistant Mycoplasma pneumoniae strains between 2018 and 2024.

Methods

We analyzed 367 patients with M. pneumoniae infection by the polymerase chain reaction method.

Results

Macrolide-resistant M. pneumoniae was identified in nine of 51 patients (17.6 %) in 2018, 13 of 63 patients (20.6 %) in 2019, eight of 30 patients (26.7 %) in 2020, one of three patients in 2021, one of three patients in 2022, three of six patients in 2023, and 127 of 211 patients (60.2 %) in 2024. Prevalence of macrolide-resistant M. pneumoniae was significantly increased in 2024 compared to the years 2018–2020 (p < 0.0001). The majority of resistant strains had an A-to-G transition at position 2063 in the M. pneumoniae 23S rRNA domain V gene region, which is associated with high-level resistance to macrolides.

Conclusions

Our study demonstrated that the prevalence of macrolide-resistant M. pneumoniae is once again increasing in Osaka Prefecture.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

大阪耐大环内酯肺炎支原体感染率再次上升

目的了解2018 - 2024年耐大环内酯肺炎支原体的流行情况及耐药机制。方法采用聚合酶链反应法对367例肺炎支原体感染患者进行分析。结果2018年51例患者中有9例（17.6%）发现耐药肺炎支原体，2019年63例患者中有13例（20.6%），2020年30例患者中有8例（26.7%），2021年3例患者中有1例，2022年3例患者中有1例，2023年6例患者中有3例，2024年211例患者中有127例（60.2%）。与2018-2020年相比，2024年耐大环内酯肺炎支原体患病率显著增加(p <；0.0001)。大多数耐药菌株在肺炎支原体23S rRNA结构域V基因区2063位发生A-to-G转变，这与对大环内酯类药物的高水平耐药有关。结论大阪府地区大环内酯类耐药肺炎支原体感染率再次上升。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊